Navigation Links
TGen becomes center of excellence for Horizon Discovery's GENESIS and X-MAN technology
Date:2/2/2010

PHOENIX, Ariz. Feb. 2, 2010 The Translational Genomics Research Institute (TGen) and Horizon Discovery today announced plans to develop human disease models for use in TGen's cancer research.

A research-collaboration and sub-licensing agreement will allow TGen investigators to use Horizon's GENESIS and X-MAN technologies to accelerate the search for new drug targets, biomarkers and anti-cancer agents, which could provide patients with more effective treatments.

Dr. Daniel Von Hoff, TGen's Physician-In-Chief and senior investigator will head the effort at TGen. Dr. Von Hoff is a leading advocate of developing precision cancer therapies. Dr. Von Hoff also is a leader in clinical trial design for agents that are based on an understanding of the cancer genes in patients' tumors.

"TGen is eager to partner with Horizon in the use of these new technologies, which should enhance our research efforts to provide patients with significantly better outcomes,'' Dr. Von Hoff said.

Horizon's core gene-targeting technology and human isogenic cell-lines are expected to enable TGen to create a key center of excellence in translational medicine for generating and applying predictive human disease models in drug discovery.

"Our over-arching mission is to speed up the research, development and prescription of more rational therapies that target the root causes of cancer development in each patient's tumor," said Dr. Chris Torrance, CEO of Horizon, based in Cambridge, U.K. "TGen investigators are visionaries in this respect and we are honored to enable them with Horizon's GENESIS technology to generate a novel pipeline of X-MAN cancer models to support cutting-edge translational oncology research."

Under terms of the collaboration, TGen will use Horizon proprietary technology and know-how to develop a panel of novel cancer cell-lines, which will be licensed back to Horizon for future licensing to the broader academic, biotech and pharma research communities. The parties also have agreed to share, publish and commercialize data from the research program, subject to future commercial terms.

This type of open-source relationship will be replicated in the future by Horizon at selected centers of excellence for translational research with the aim of deciphering the genetic links to cancer and other debilitating diseases.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology news :

1. UNH becomes first university in nation to use landfill gas as primary energy source
2. Scientists find how amber becomes death trap for watery creatures
3. Complete Genomics launches, becomes worlds first large-scale human genome sequencing company
4. Time running out on coral reefs as climate change becomes increasing threat
5. Italys geologic history becomes a personal tale in Walter Alvarezs new book
6. Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find
7. Georgia Tech/Emory Center to study origin of life
8. Woods Hole Research Center to lead undergraduate initiative in the Siberian Arctic
9. $10 million gift to support cutting-edge epigenome center at USC
10. 3 Columbia University Medical Center faculty elected to Institute of Medicine
11. NHGRI funds new Centers for Excellence in Ethical, Legal and Social Implications Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... a global clinical research organization (CRO), announces the launch of Shadow, ... 2017. Shadow is designed to assist medical writers and biometrics teams ... European Medicines Agency (EMA) in meeting the requirements for de-identifying clinical ... ... Tom ...
(Date:6/30/2017)... Today, American Trucking Associations announced Seeing ... and eye tracking software, became the newest member ... "Artificial intelligence and advanced sensing algorithms ... driver,s attentiveness levels while on the road.  Drivers ... fatigue and prevent potential accidents, which could lead ...
(Date:5/16/2017)...  Veratad Technologies, LLC ( www.veratad.com ), an innovative ... verification solutions, announced today they will participate as a ... thru May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions ... evolving digital world, defining identity is critical to nearly ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... ... Rosalind™, the first-ever genomics analysis platform specifically designed for life science researchers ... honor of pioneering researcher Rosalind Franklin, who made a major contribution to ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ComplianceOnline’s Medical Device ... on 7th and 8th June 2018 in San Francisco, CA. The Summit brings together ... as several distinguished CEOs, board directors and government officials from around the world to ...
(Date:10/11/2017)... Georgia (PRWEB) , ... October 11, 2017 , ... Disappearing ... taking the lives of over 5.5 million people each year. Especially those living in ... greenovative startup Treepex - based in one of the most pollution-affected countries globally - ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
Breaking Biology Technology: